Estimating The Intrinsic Value Of ICON Public Limited Company (NASDAQ:ICLR)
Key Insights ICON's estimated fair value is US$413 based on 2 Stage Free Cash Flow to Equity Current share price of US$336 suggests ICON is potentially trading close to its fair value The US$364
Here's Why Icon PLC (ICLR) Is a Strong Value Stock
Express News | ICON Recognised for Leadership Position in Clinical Research Industry and as Socially Responsible Employer
Drug Middlemen Pay Higher Prices to Their Own Pharmacies, Says FTC
(July 9): Drug middlemen paid their own mail-order pharmacies as much as 200 times more than the price at rival pharmacies for commonly prescribed cancer drugs, allowing them to bring in at least US$1 billion (RM4.71 billion) in excess revenue and potentially raising the costs to patients, the US Federal Trade Commission (FTC) found in an interim study.
Here's How Much You Would Have Made Owning Icon Stock In The Last 15 Years
Icon (NASDAQ:ICLR) has outperformed the market over the past 15 years by 6.54% on an annualized basis producing an average annual return of 19.38%. Currently, Icon has a market capitalization of $26.5
Icon Is Maintained at Outperform by Baird
Icon Is Maintained at Outperform by Baird
Icon Price Target Raised to $376.00/Share From $367.00 by Baird
Icon Price Target Raised to $376.00/Share From $367.00 by Baird
Baird Maintains Icon PLC(ICLR.US) With Buy Rating, Raises Target Price to $376
Baird analyst Eric Coldwell maintains $Icon PLC(ICLR.US)$ with a buy rating, and adjusts the target price from $367 to $376.According to TipRanks data, the analyst has a success rate of 52.2% and a to
Express News | ICON PLC : Baird Raises Target Price to $376 From $367
Deutsche Bank's Fresh Money List for 3Q
ICON Plc Schedules Second Quarter 2024 Earnings Conference Call
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on
Should Weakness in ICON Public Limited Company's (NASDAQ:ICLR) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
ICON (NASDAQ:ICLR) has had a rough three months with its share price down 6.8%. But if you pay close attention, you might find that its key financial indicators look quite decent, which could mean t
Is Icon PLC (ICLR) a Solid Growth Stock? 3 Reasons to Think "Yes"
Barclays Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $355
Barclays analyst Luke Sergott maintains $Icon PLC(ICLR.US)$ with a buy rating, and maintains the target price at $355.According to TipRanks data, the analyst has a success rate of 39.9% and a total av
Here's Why Icon PLC (ICLR) Is a Strong Momentum Stock
Why Icon PLC (ICLR) Is a Top Growth Stock for the Long-Term
$100 Invested In This Stock 15 Years Ago Would Be Worth $1,400 Today
Icon (NASDAQ:ICLR) has outperformed the market over the past 15 years by 6.88% on an annualized basis producing an average annual return of 19.66%. Currently, Icon has a market capitalization of $26.3
Here's Why ICON (NASDAQ:ICLR) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to rui
Is Now The Time To Put ICON (NASDAQ:ICLR) On Your Watchlist?
Global Cardiovascular Clinical Trials Market Size To Exceed USD 9.76 Billion By 2033 L a CAGR of 6.18%